Roquefort Therapeutics (LON:ROQ) Trading Down 13.8% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) shares were down 13.8% on Tuesday . The stock traded as low as GBX 1.91 ($0.02) and last traded at GBX 2.07 ($0.03). Approximately 14,477,742 shares were traded during mid-day trading, an increase of 478% from the average daily volume of 2,502,635 shares. The stock had previously closed at GBX 2.40 ($0.03).

Roquefort Therapeutics Price Performance

The company has a fifty day simple moving average of GBX 2.99 and a two-hundred day simple moving average of GBX 3.65. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79. The company has a market capitalization of £2.55 million, a price-to-earnings ratio of -1.65 and a beta of 0.05.

Insider Buying and Selling at Roquefort Therapeutics

In other Roquefort Therapeutics news, insider Stephen Paul West purchased 400,000 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was bought at an average cost of GBX 3 ($0.04) per share, for a total transaction of £12,000 ($15,449.98). 60.40% of the stock is currently owned by insiders.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.